Kinase Inhibitor Scaffold Hopping with Deep Learning Approaches

被引:12
作者
Hu, Lizhao [1 ,2 ]
Yang, Yuyao [2 ,3 ]
Zheng, Shuangjia [4 ]
Xu, Jun [1 ,2 ]
Ran, Ting [3 ]
Chen, Hongming [3 ]
机构
[1] Wuyi Univ, Sch Biotechnol & Hlth Sci, Jiangmen 529020, Peoples R China
[2] Sun Yat Sen Univ, Res Ctr Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China
[3] Ctr Cell Lineage & Atlas Bioland Lab, Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510530, Peoples R China
[4] Sun Yat Sen Univ, Sch Data & Comp Sci, Guangzhou 510006, Peoples R China
基金
国家重点研发计划;
关键词
PROTEIN-KINASES; DRUG DISCOVERY; DESIGN; FRAGMENTS; SELECTION; DOCKING; UPDATE; JAK2;
D O I
10.1021/acs.jcim.1c00608
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The protein kinase family contains many promising drug targets. Many kinase inhibitors target the ATP-binding pocket, leading to approved drugs in past decades. Scaffold hopping is an effective approach for drug design. The kinase ATP-binding pocket is highly conserved, crossing the whole kinase family. This provides an opportunity to develop a scaffold hopping approach to explore diversified scaffolds among various kinase inhibitors. In this work, we report the SyntaLinker-Hybrid scheme for kinase inhibitor scaffold hopping. With this scheme, we replace molecular fragments bound at the conserved kinase hinge region with deep generative models. Thus, we are able to generate new kinase-inhibitor-like structures hybridizing the privileged fragments against the hinge region. We demonstrate that this scheme allows generation of kinase-inhibitor-like molecules with novel scaffolds, while retaining the binding features of existing kinase inhibitors. This work can be employed in lead identification against kinase targets.
引用
收藏
页码:4900 / 4912
页数:13
相关论文
共 47 条
  • [1] Guidelines for Recurrent Neural Network Transfer Learning-Based Molecular Generation of Focused Libraries
    Amabilino, Silvia
    Pogany, Peter
    Pickett, Stephen D.
    Green, Darren V. S.
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2020, 60 (12) : 5699 - 5713
  • [2] Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update
    Arunesh, Gubbi M.
    Shanthi, Ekambaram
    Krishna, Mudeenahally H.
    Kumar, Jegatheesan Sooriya
    Viswanadhan, Vellarkad N.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (01) : 5 - 17
  • [3] A Comprehensive Structural Overview of p38 MAPK in Complex with TypeI Inhibitors
    Astolfi, Andrea
    Iraci, Nunzio
    Manfroni, Giuseppe
    Barreca, Maria Letizia
    Cecchetti, Violetta
    [J]. CHEMMEDCHEM, 2015, 10 (06) : 957 - 969
  • [4] The properties of known drugs .1. Molecular frameworks
    Bemis, GW
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 2887 - 2893
  • [5] GuacaMol: Benchmarking Models for de Novo Molecular Design
    Brown, Nathan
    Fiscato, Marco
    Segler, Marwin H. S.
    Vaucher, Alain C.
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2019, 59 (03) : 1096 - 1108
  • [6] Unsupervised data base clustering based on Daylight's fingerprint and Tanimoto similarity: A fast and automated way to cluster small and large data sets
    Butina, D
    [J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1999, 39 (04): : 747 - 750
  • [7] Research progress of mTOR inhibitors
    Chen, Yifan
    Zhou, Xiaoping
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 208
  • [8] Chohan TA, 2015, CURR MED CHEM, V22, P237
  • [9] Protein kinases - the major drug targets of the twenty-first century?
    Cohen, P
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) : 309 - 315
  • [10] Kinase Drug Discovery - What's Next in the Field?
    Cohen, Philip
    Alessi, Dario R.
    [J]. ACS CHEMICAL BIOLOGY, 2013, 8 (01) : 96 - 104